B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Key Account Manager

Full-Time
CHF156.8k - CHF196k
Senior
Bachelor's, MBA, PhD, MD
Basel, Switzerland
HybridApproximately 70% of working time is spent in field/customer-facing activities; willingness to travel is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A life science degree from a university or college, or equivalent professional experience.
  • At least seven years of qualified work experience as a commercial representative in the hemato-oncology market.
  • Scientific education and experience in this or similar positions.
  • Specific knowledge of hematology-oncology and distinct knowledge of project management.
  • Strong identification with BeOne’s values.
  • Willingness to learn and continuously develop through training and coaching.
  • Demonstrated success in a small, fast-growing, entrepreneurial commercial environment.
  • Implementation skills and the ability to make things happen.
  • Marketing- and commercially oriented thinking and working.
  • Knowledge of drug distribution structures and channels.
  • High social competence and ability to work in a team environment.
  • Success-, service-, and commercial-oriented thinking and working.
  • Fluency in English and German; Italian and/or French are advantageous.
  • Ability to conduct complex scientific, commercial, and institutional discussions in Dutch and English, as stated under Communication.
  • Willingness to travel and a valid driver’s license.
  • Standard computer skills, including MS Office.
  • Fluency in verbal and written English and the country language; any other major European language is also mentioned.
  • A university undergraduate degree in science or business is preferred; higher qualifications (MD, PhD, MBA) are advantageous. This education statement is listed under Education Required in the posting.
Responsibilities
  • Own priority hospital accounts, build relationships with clinical and institutional stakeholders, and develop a deep understanding of patient pathways, access, competitive dynamics, and unmet needs.
  • Develop and execute patient-centric account plans that translate strategy and insights into prioritized opportunities and actions to optimize patient care.
  • Strengthen BeOne’s image, reputation, and credibility as a trusted partner in the Swiss healthcare landscape.
  • Deliver regional sales goals and agreed account, coverage, and quality KPIs, proactively identifying and addressing performance gaps.
  • Lead customer engagement with hematologists and other stakeholders, using insights into patient potential, treatment pathways, prescribing trends, and competition to identify growth opportunities and support patient care.
  • Coordinate engagement across face-to-face, remote, and approved digital channels, including local, national, and international meetings, symposia, and workshops.
  • Work with Marketing and Medical to represent BeOne products consistently with brand strategy and scientific standards.
  • Maintain effective customer coverage and engagement frequency, spending approximately 70% of working time in field/customer-facing activities.
  • Maintain accurate CRM documentation and use CRM to plan and track account progression.
  • Develop and lead commercial projects with key customers addressing clinical, educational, or operational needs and contributing to patient care.
  • Conduct activities ethically and in accordance with BeOne standards, applicable laws, regulations, codes, and company policies.
  • Fulfil pharmacovigilance, medical inquiry, and product-quality reporting obligations.
  • Act as a role model for ethical, patient-centric behaviour within the field team.
  • Understand hospital account dynamics and tailor consistent evidence to different audiences.
  • Listen and probe to understand account needs and translate them into value-added service initiatives.
  • Understand patient flows, treatment sequencing, prescriber behaviour, and incumbent share, and identify triggers for changing account-level treatment decisions.
  • Combine face-to-face, remote, virtual, and approved digital engagement into a coherent customer journey, adapting channels to stakeholder preferences, access constraints, CRM insights, and account objectives.
  • Coordinate proactively with Medical Science Liaisons, FCM, and Marketing by sharing intelligence, aligning account priorities, and ensuring handoffs.
  • Set SMART account objectives, document customer interactions and next steps, follow through on commitments, escalate barriers, and remain accountable for activity quality, account progression, and business outcomes.
  • Adapt to constrained healthcare-professional access, cost-driven prescribing, incumbent competition, and organizational change, finding alternative routes to impact when conventional access is blocked.
  • Operate with integrity, transparency, and respect, following regulatory and company standards and treating patient safety, ethical conduct, and compliance as personal responsibilities.
  • Apply analytical thinking, structured problem-solving, organized planning, project management, disciplined delivery, and feedback to improve performance and outcomes.
  • Listen, clarify, and respond to questions; conduct complex scientific, commercial, and institutional discussions in Dutch and English.
Desired Qualifications
  • Excellent, reliable contacts with opinion leaders in relevant indications, especially in the field of lymphomas.
  • Italian and/or French language skills.
  • A university undergraduate degree in science or business; MD, PhD, or MBA qualifications are advantageous.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.